Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Prior treatment

• Long-term use of immunosuppressive agents following organ transplantation
• Current use of immunosuppressive medications
• Receipt of traditional Chinese herbal medicines with antitumor indications or immunomodulatory agents within 14 days prior to the first dose of study drug
• Ongoing systemic therapy (including thymosin, interferon, or interleukins; local use for control of pleural effusion is permitted)
• Concurrent enrollment in another clinical study, unless it is an observational/non-interventional study or the follow-up phase of an interventional study

Other illness

• Poor general condition precluding tolerance of general anesthesia based on anesthesiological assessment
• Severe cardiovascular or cerebrovascular disease, uncontrolled hypertension, or uncontrolled diabetes mellitus
• Active or clinically apparent infection or fever
• Concurrent other malignancies, currently undergoing treatment for other benign or malignant tumors, or a history of other malignancies within the preceding 6 months
• Active or potentially relapsing autoimmune disease; the following conditions are exempt: vitiligo, alopecia, psoriasis, or eczema not requiring systemic treatment; hypothyroidism secondary to autoimmune thyroiditis requiring only stable-dose hormone replacement therapy; type 1 diabetes mellitus requiring only stable-dose insulin replacement therapy
• Known history of psychiatric illness, substance abuse, alcohol dependence, or illicit drug use

Lab values

• Any concurrent disease, prior treatment, or laboratory abnormality that may confound study results, interfere with the subject's full study participation, or indicate that participation may not be in the subject's best interest

Other

• Patients meeting any of the following criteria will be ineligible for participation:
• Lymph node metastasis
• Tumor encasing the renal artery
• Tumor thrombus within the renal vein
• Diffuse tumor growth without a clear boundary with normal renal parenchyma
• T-cell lymphoma or multiple myeloma
• Metastatic renal cell carcinoma
• Pregnant or breastfeeding women

• Voluntary provision of written informed consent prior to any study-related procedures.
• Age ≥18 years at the time of enrollment; no restriction on sex.
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
• Estimated survival ≥3 months.
• Pathological confirmation of clear cell RCC or predominantly clear cell renal cell carcinoma by preoperative needle biopsy.
• Patient willingness to undergo nephron-sparing surgery.
• Presence of indications for nephron-sparing surgery but with high surgical complexity: 1) tumors measuring 4-7 cm located at the renal hilum or with endophytic growth ≥75%; or 2) tumors \>7 cm.
• At least one measurable lesion per RECIST v1.1 criteria, suitable for repeated accurate measurement.
• Adequate organ function, with laboratory results during the screening period meeting all of the following criteria:
  • Hematology (no blood component or colony-stimulating factor support permitted within 2 weeks prior to treatment initiation):
  • Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L (≥1,500/mm³)
  • Platelet count (PLT) ≥100 × 10⁹/L (≥100,000/mm³)
  • Hemoglobin (Hb) ≥90 g/L
  • Hepatic function:
  • Serum total bilirubin (TBIL) ≤1.5 × ULN
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN
  • Serum albumin (ALB) ≥28 g/L
  • Coagulation:
  • \- International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤1.5 × ULN
• Willingness and ability to comply with scheduled visits, treatment plans, laboratory assessments, and all other study requirements.